伊布替尼治疗期间慢性淋巴细胞白血病患者偶然发生 Richter 转化。
Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib.
机构信息
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Department of Leukemia and.
出版信息
Blood Adv. 2020 Sep 22;4(18):4508-4511. doi: 10.1182/bloodadvances.2020002454.
Abstract
An incidental histologic diagnosis of DLBCL was identified during temporary interruption of ibrutinib treatment in patients with CLL. In contrast to an aggressive clinical course typical of Richter transformation, these patients responded to reinitiation of ibrutinib alone.
摘要
在慢性淋巴细胞白血病（CLL）患者中断伊布替尼治疗期间偶然发现弥漫性大 B 细胞淋巴瘤（DLBCL）的组织学诊断。与典型 Richter 转化的侵袭性临床病程相反，这些患者对重新开始单独使用伊布替尼有反应。
相似文献
1
Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib.伊布替尼治疗期间慢性淋巴细胞白血病患者偶然发生 Richter 转化。
Blood Adv. 2020 Sep 22;4(18):4508-4511. doi: 10.1182/bloodadvances.2020002454.
2
Pseudo-Richter transformation of chronic lymphocytic leukaemia/small lymphocytic lymphoma following ibrutinib interruption: a diagnostic pitfall.依鲁替尼中断治疗后慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的假性里氏转化：一个诊断陷阱
Br J Haematol. 2020 Oct;191(1):e22-e25. doi: 10.1111/bjh.16948. Epub 2020 Jul 17.
3
Richter transformation heralded by EBV reactivation during ibrutinib therapy for chronic lymphocytic leukemia.
Leuk Lymphoma. 2021 Dec;62(12):3051-3053. doi: 10.1080/10428194.2021.1964023. Epub 2021 Aug 25.
4
Early Transformation to Classic Hodgkin Lymphoma in a Chemotherapy-naïve Chronic Lymphocytic Leukemia Patient upon Initial Treatment with Ibrutinib.伊布替尼初治时慢性淋巴细胞白血病患者未化疗即早期转化为经典型霍奇金淋巴瘤。
Intern Med. 2021 Oct 15;60(20):3305-3308. doi: 10.2169/internalmedicine.6979-20. Epub 2021 Apr 26.
5
Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia.慢性淋巴细胞白血病患者伊布替尼治疗临时中断期间的疾病 flares。
Oncologist. 2020 Nov;25(11):974-980. doi: 10.1634/theoncologist.2020-0388. Epub 2020 Sep 20.
6
Ibrutinib Regimens in Older Patients with Untreated CLL.伊布替尼方案用于未经治疗的老年慢性淋巴细胞白血病患者
N Engl J Med. 2019 Apr 25;380(17):1679. doi: 10.1056/NEJMc1901284.
7
Ibrutinib Regimens in Older Patients with Untreated CLL.伊布替尼方案用于未经治疗的老年慢性淋巴细胞白血病患者
N Engl J Med. 2019 Apr 25;380(17):1679. doi: 10.1056/NEJMc1901284.
8
Ibrutinib Regimens in Older Patients with Untreated CLL.伊布替尼方案用于未治疗的老年慢性淋巴细胞白血病患者
N Engl J Med. 2019 Apr 25;380(17):1679-1681. doi: 10.1056/NEJMc1901284.
9
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.依鲁替尼联合纳武单抗治疗复发非霍奇金淋巴瘤或慢性淋巴细胞白血病患者的安全性和活性：一项1/2a期研究
Lancet Haematol. 2019 Feb;6(2):e67-e78. doi: 10.1016/S2352-3026(18)30217-5. Epub 2019 Jan 11.
10
Ibrutinib Restores Tumor-specific Adaptive Immunity in Chronic Lymphocytic Leukemia.依鲁替尼可恢复慢性淋巴细胞白血病中的肿瘤特异性适应性免疫。
Clin Cancer Res. 2021 Aug 15;27(16):4465-4467. doi: 10.1158/1078-0432.CCR-21-1589. Epub 2021 Jun 9.
引用本文的文献
1
Atypical lymphoid proliferations associated with therapeutic intervention: a report of the 2024 EA4HP/SH lymphoma workshop.与治疗干预相关的非典型淋巴样增殖：2024年EA4HP/SH淋巴瘤研讨会报告
Virchows Arch. 2025 Aug 13. doi: 10.1007/s00428-025-04197-0.
2
Decreased apoptotic priming and loss of BCL-2 dependence are functional hallmarks of Richter's syndrome.凋亡起始减少和 BCL-2 依赖性丧失是里希特综合征的功能标志。
Cell Death Dis. 2024 May 9;15(5):323. doi: 10.1038/s41419-024-06707-5.
3
Richter Transformation of Chronic Lymphocytic Leukemia-Are We Making Progress?慢性淋巴细胞白血病的 Richter 转化——我们是否取得了进展？
Curr Hematol Malig Rep. 2023 Oct;18(5):144-157. doi: 10.1007/s11899-023-00701-y. Epub 2023 Jun 9.
4
[Classification of indolent B-cell lymphomas : Novelties and open questions].[惰性B细胞淋巴瘤的分类：新进展与未决问题]
Pathologie (Heidelb). 2023 May;44(3):154-165. doi: 10.1007/s00292-023-01186-5. Epub 2023 Apr 24.
5
Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop.慢性淋巴细胞白血病/小淋巴细胞淋巴瘤和 B 细胞幼淋巴细胞白血病的进展和转化：来自 2021 年 SH/EAHP 研讨会的报告。
Am J Clin Pathol. 2023 Jun 1;159(6):554-571. doi: 10.1093/ajcp/aqad027.
6
Chronic lymphocytic leukemia treatment algorithm 2022.2022 年慢性淋巴细胞白血病治疗算法
Blood Cancer J. 2022 Nov 29;12(11):161. doi: 10.1038/s41408-022-00756-9.
7
An Approach to Diagnosis of Richter Transformation in Chronic Lymphocytic Leukemia.慢性淋巴细胞白血病Richter转化的诊断方法
J Adv Pract Oncol. 2022 Jul;13(5):535-538. doi: 10.6004/jadpro.2022.13.5.7. Epub 2022 Jul 27.
8
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.成熟淋巴细胞肿瘤国际共识分类：临床咨询委员会报告。
Blood. 2022 Sep 15;140(11):1229-1253. doi: 10.1182/blood.2022015851.
9
Biology and Treatment of Richter Transformation.里氏转化的生物学特性与治疗
Front Oncol. 2022 Mar 22;12:829983. doi: 10.3389/fonc.2022.829983. eCollection 2022.
10
Life-Threatening Fungal Infection in Richter Transformation of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Case Report and Brief Review of Literature.慢性淋巴细胞白血病/小淋巴细胞淋巴瘤Richter转化中的危及生命的真菌感染：一例报告并文献简要回顾
Cureus. 2021 Jun 25;13(6):e15924. doi: 10.7759/cureus.15924. eCollection 2021 Jun.
本文引用的文献
1
Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center.Richter 转化的临床特征和结局：单中心 204 例患者的经验。
Haematologica. 2020 Mar;105(3):765-773. doi: 10.3324/haematol.2019.224121. Epub 2019 Jun 13.
2
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.3 项关键性研究中单药伊布替尼治疗慢性淋巴细胞白血病患者的长期安全性。
Blood Adv. 2019 Jun 25;3(12):1799-1807. doi: 10.1182/bloodadvances.2018028761.
3
Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice.在常规临床实践中治疗的慢性淋巴细胞白血病患者停止伊布替尼治疗后疾病迅速进展。
Leuk Lymphoma. 2019 Nov;60(11):2712-2719. doi: 10.1080/10428194.2019.1602268. Epub 2019 Apr 24.
4
Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL.临床指示的依鲁替尼剂量中断和减少不会损害慢性淋巴细胞白血病（CLL）的长期治疗效果。
Blood. 2019 May 30;133(22):2452-2455. doi: 10.1182/blood.2019896688. Epub 2019 Mar 27.
5
PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness.PD-1 在慢性淋巴细胞白血病/小淋巴细胞淋巴瘤 (CLL/SLL) 和大 B 细胞 Richter 转化 (DLBCL-RT) 中的表达：DLBCL-RT 的特征性特征和潜在的克隆相关性替代标志物。
Am J Surg Pathol. 2018 Jul;42(7):843-854. doi: 10.1097/PAS.0000000000001077.
6
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.iwCLL 指南：用于 CLL 的诊断、治疗指征、疗效评估和支持性管理。
Blood. 2018 Jun 21;131(25):2745-2760. doi: 10.1182/blood-2017-09-806398. Epub 2018 Mar 14.
7
Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.伊布替尼、idelalisib 和 venetoclax 在慢性淋巴细胞白血病中的最佳序贯治疗：来自 683 例患者的多中心研究结果。
Ann Oncol. 2017 May 1;28(5):1050-1056. doi: 10.1093/annonc/mdx031.
8
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.依鲁替尼剂量依从性对既往治疗的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者治疗疗效的影响。
Blood. 2017 May 11;129(19):2612-2615. doi: 10.1182/blood-2016-12-737346. Epub 2017 Apr 3.
9
Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.停用依鲁替尼的慢性淋巴细胞白血病患者的长期预后。
Cancer. 2017 Jun 15;123(12):2268-2273. doi: 10.1002/cncr.30596. Epub 2017 Feb 7.
10
Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients.伊布替尼用于复发/难治性慢性淋巴细胞白血病：英国和爱尔兰315例患者的疗效分析。
Haematologica. 2016 Dec;101(12):1563-1572. doi: 10.3324/haematol.2016.147900. Epub 2016 Oct 18.
Zotero 插件